264 related articles for article (PubMed ID: 33004686)
1. CAR T cells targeting tumor endothelial marker CLEC14A inhibit tumor growth.
Zhuang X; Maione F; Robinson J; Bentley M; Kaul B; Whitworth K; Jumbu N; Jinks E; Bystrom J; Gabriele P; Garibaldi E; Delmastro E; Nagy Z; Gilham D; Giraudo E; Bicknell R; Lee SP
JCI Insight; 2020 Oct; 5(19):. PubMed ID: 33004686
[TBL] [Abstract][Full Text] [Related]
2. A Novel Siglec-4 Derived Spacer Improves the Functionality of CAR T Cells Against Membrane-Proximal Epitopes.
Schäfer D; Henze J; Pfeifer R; Schleicher A; Brauner J; Mockel-Tenbrinck N; Barth C; Gudert D; Al Rawashdeh W; Johnston ICD; Hardt O
Front Immunol; 2020; 11():1704. PubMed ID: 32849600
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of VEGF-dependent angiogenesis and tumor angiogenesis by an optimized antibody targeting CLEC14a.
Kim TK; Park CS; Jang J; Kim MR; Na HJ; Lee K; Kim HJ; Heo K; Yoo BC; Kim YM; Lee JW; Kim SJ; Kim ES; Kim DY; Cha K; Lee TG; Lee S
Mol Oncol; 2018 Mar; 12(3):356-372. PubMed ID: 29316206
[TBL] [Abstract][Full Text] [Related]
4. Mesothelin CAR T Cells Secreting Anti-FAP/Anti-CD3 Molecules Efficiently Target Pancreatic Adenocarcinoma and its Stroma.
Wehrli M; Guinn S; Birocchi F; Kuo A; Sun Y; Larson RC; Almazan AJ; Scarfò I; Bouffard AA; Bailey SR; Anekal PV; Montero Llopis P; Nieman LT; Song Y; Xu KH; Berger TR; Kann MC; Leick MB; Silva H; Salas-Benito D; Kienka T; Grauwet K; Armstrong TD; Zhang R; Zhu Q; Fu J; Schmidts A; Korell F; Jan M; Choi BD; Liss AS; Boland GM; Ting DT; Burkhart RA; Jenkins RW; Zheng L; Jaffee EM; Zimmerman JW; Maus MV
Clin Cancer Res; 2024 May; 30(9):1859-1877. PubMed ID: 38393682
[TBL] [Abstract][Full Text] [Related]
5. Antitumor Responses in the Absence of Toxicity in Solid Tumors by Targeting B7-H3 via Chimeric Antigen Receptor T Cells.
Du H; Hirabayashi K; Ahn S; Kren NP; Montgomery SA; Wang X; Tiruthani K; Mirlekar B; Michaud D; Greene K; Herrera SG; Xu Y; Sun C; Chen Y; Ma X; Ferrone CR; Pylayeva-Gupta Y; Yeh JJ; Liu R; Savoldo B; Ferrone S; Dotti G
Cancer Cell; 2019 Feb; 35(2):221-237.e8. PubMed ID: 30753824
[TBL] [Abstract][Full Text] [Related]
6. Multimerin-2 is a ligand for group 14 family C-type lectins CLEC14A, CD93 and CD248 spanning the endothelial pericyte interface.
Khan KA; Naylor AJ; Khan A; Noy PJ; Mambretti M; Lodhia P; Athwal J; Korzystka A; Buckley CD; Willcox BE; Mohammed F; Bicknell R
Oncogene; 2017 Nov; 36(44):6097-6108. PubMed ID: 28671670
[TBL] [Abstract][Full Text] [Related]
7. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
[TBL] [Abstract][Full Text] [Related]
8. Identification and angiogenic role of the novel tumor endothelial marker CLEC14A.
Mura M; Swain RK; Zhuang X; Vorschmitt H; Reynolds G; Durant S; Beesley JF; Herbert JM; Sheldon H; Andre M; Sanderson S; Glen K; Luu NT; McGettrick HM; Antczak P; Falciani F; Nash GB; Nagy ZS; Bicknell R
Oncogene; 2012 Jan; 31(3):293-305. PubMed ID: 21706054
[TBL] [Abstract][Full Text] [Related]
9. Effective Targeting of TAG72
Murad JP; Kozlowska AK; Lee HJ; Ramamurthy M; Chang WC; Yazaki P; Colcher D; Shively J; Cristea M; Forman SJ; Priceman SJ
Front Immunol; 2018; 9():2268. PubMed ID: 30510550
[TBL] [Abstract][Full Text] [Related]
10. TEM8/ANTXR1-specific CAR T cells mediate toxicity in vivo.
Petrovic K; Robinson J; Whitworth K; Jinks E; Shaaban A; Lee SP
PLoS One; 2019; 14(10):e0224015. PubMed ID: 31622431
[TBL] [Abstract][Full Text] [Related]
11. Chimeric antigen receptor T cell targeting EGFRvIII for metastatic lung cancer therapy.
Zhang Z; Jiang J; Wu X; Zhang M; Luo D; Zhang R; Li S; He Y; Bian H; Chen Z
Front Med; 2019 Feb; 13(1):57-68. PubMed ID: 30721445
[TBL] [Abstract][Full Text] [Related]
12. Chimeric antigen receptor (CAR)-T-cell therapy in non-small-cell lung cancer (NSCLC): current status and future perspectives.
Qu J; Mei Q; Chen L; Zhou J
Cancer Immunol Immunother; 2021 Mar; 70(3):619-631. PubMed ID: 33025047
[TBL] [Abstract][Full Text] [Related]
13. Human antibodies targeting the C-type lectin-like domain of the tumor endothelial cell marker clec14a regulate angiogenic properties in vitro.
Ki MK; Jeoung MH; Choi JR; Rho SS; Kwon YG; Shim H; Chung J; Hong HJ; Song BD; Lee S
Oncogene; 2013 Nov; 32(48):5449-57. PubMed ID: 23644659
[TBL] [Abstract][Full Text] [Related]
14. Research progress and design optimization of CAR-T therapy for pancreatic ductal adenocarcinoma.
Li T; Li H; Li S; Xu S; Zhang W; Gao H; Xu H; Wu C; Wang W; Yu X; Liu L
Cancer Med; 2019 Sep; 8(11):5223-5231. PubMed ID: 31339230
[TBL] [Abstract][Full Text] [Related]
15. An evaluation of the tumour endothelial marker CLEC14A as a therapeutic target in solid tumours.
Robinson J; Whitworth K; Jinks E; Nagy Z; Bicknell R; Lee SP
J Pathol Clin Res; 2020 Oct; 6(4):308-319. PubMed ID: 32696621
[TBL] [Abstract][Full Text] [Related]
16. CD27 enhances the killing effect of CAR T cells targeting trophoblast cell surface antigen 2 in the treatment of solid tumors.
Chen H; Wei F; Yin M; Zhao Q; Liu Z; Yu B; Huang Z
Cancer Immunol Immunother; 2021 Jul; 70(7):2059-2071. PubMed ID: 33439295
[TBL] [Abstract][Full Text] [Related]
17. Recombination of a dual-CAR-modified T lymphocyte to accurately eliminate pancreatic malignancy.
Zhang E; Yang P; Gu J; Wu H; Chi X; Liu C; Wang Y; Xue J; Qi W; Sun Q; Zhang S; Hu J; Xu H
J Hematol Oncol; 2018 Aug; 11(1):102. PubMed ID: 30103775
[TBL] [Abstract][Full Text] [Related]
18. Blocking CLEC14A-MMRN2 binding inhibits sprouting angiogenesis and tumour growth.
Noy PJ; Lodhia P; Khan K; Zhuang X; Ward DG; Verissimo AR; Bacon A; Bicknell R
Oncogene; 2015 Nov; 34(47):5821-31. PubMed ID: 25745997
[TBL] [Abstract][Full Text] [Related]
19. Chimeric antigen receptor T cell therapy in pancreatic cancer: from research to practice.
Jindal V; Arora E; Masab M; Gupta S
Med Oncol; 2018 May; 35(6):84. PubMed ID: 29728788
[TBL] [Abstract][Full Text] [Related]
20. Tandem CAR-T cells targeting CD70 and B7-H3 exhibit potent preclinical activity against multiple solid tumors.
Yang M; Tang X; Zhang Z; Gu L; Wei H; Zhao S; Zhong K; Mu M; Huang C; Jiang C; Xu J; Guo G; Zhou L; Tong A
Theranostics; 2020; 10(17):7622-7634. PubMed ID: 32685008
[No Abstract] [Full Text] [Related]
[Next] [New Search]
